Revenue Performance - Software revenue represented 94% of total revenue for the three months ended September 30, 2025, and 95% for the same period in 2024[131]. - Total revenue for the three months ended September 30, 2025, was $154.3 million, an increase of $25.2 million, or 19%, compared to $129.1 million for the same period in 2024[169]. - Subscription revenue reached $140.9 million, accounting for 91% of total revenue, representing a 27% increase from $110.7 million, or 86% of total revenue, in the prior year[170]. - License revenue decreased by 64% to $4.2 million, or 3% of total revenue, down from $11.7 million, or 9% of total revenue, in the same quarter of 2024[171]. - Professional services and other revenue increased by 38% to $9.2 million, or 6% of total revenue, compared to $6.7 million, or 5% of total revenue, in the prior year[172]. - Total revenue for the nine months ended September 30, 2025 was $438.2 million, an increase of $81.3 million, or 23%, compared to $356.9 million for the same period in 2024[188]. - Subscription revenue for the nine months ended September 30, 2025 was $399.7 million, representing a 29% increase from $309.5 million in the same period of 2024[189]. Customer Growth - The company had 1,739 customers as of September 30, 2025, reflecting a year-over-year growth of 13% from 1,534 customers in 2024[142]. - Revenue from customers outside the United States accounted for 34% of total revenue for the three months ended September 30, 2025, compared to 29% in 2024[134]. - The majority of new customers have been on SaaS contracts, which have accounted for more than 90% of new customer contracts since 2023[132]. Financial Metrics - Gross profit for the three months ended September 30, 2025, was $105.1 million, compared to $64.7 million in the same period of 2024[165]. - Gross margin improved to 68% for the three months ended September 30, 2025, compared to 50% for the same period in 2024[167]. - Operating expenses totaled $122.5 million for the three months ended September 30, 2025, compared to $319.9 million in the same period of 2024[165]. - The net loss attributable to OneStream, Inc. for the three months ended September 30, 2025, was $8.9 million, compared to a net loss of $171.9 million in the same period of 2024[165]. - Non-GAAP operating loss for the nine months ended September 30, 2025, was $89.6 million, an improvement from a loss of $272.1 million for the same period in 2024[209]. - Free cash flow for the nine months ended September 30, 2025, was $70.0 million, compared to $33.8 million for the same period in 2024[210]. Cost Management - Total cost of revenue decreased by 24% to $49.3 million for the three months ended September 30, 2025, down from $64.4 million in the same period of 2024[173]. - Sales and marketing expenses decreased by 61% to $63.5 million for the three months ended September 30, 2025, down from $162.7 million in the same period of 2024[179]. - Research and development expenses were $30.6 million for the three months ended September 30, 2025, a decrease of 63% from $83.0 million in the same period of 2024[180]. - General and administrative expenses decreased by $22.9 million, or 21%, to $87.6 million for the nine months ended September 30, 2025, compared to $110.5 million for the same period in 2024[201]. Future Outlook - The company plans to continue investing in research and development to enhance platform features and capabilities, including AI-enabled solutions[148]. - The company plans to increase investments in sales and marketing, as well as research and development, to support future growth[161][162]. - The company is focused on expanding its international business and plans to invest in personnel and marketing to support this growth[147]. Cash and Liquidity - As of September 30, 2025, the company had cash and cash equivalents of $653.9 million and an undrawn credit facility of $150.0 million[211]. - Net cash provided by operating activities for the nine months ended September 30, 2025, was $70.9 million, resulting from a net loss of $69.0 million offset by noncash charges[223]. - Total contractual obligations as of September 30, 2025, amounted to $42.15 million, with operating lease obligations of $20.69 million and purchase obligations of $21.46 million[230]. Market and Economic Conditions - The company has not entered into any foreign currency hedging contracts, as exchange rate fluctuations have not materially impacted operating results[240]. - The company expects to continue growing its foreign operations and customer sales, which may increase risks associated with currency fluctuations[240]. - Inflation has not had a material effect on the company's business; however, significant inflationary pressures could harm financial condition and results of operations[242].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________ FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Weave Communications, Inc. (Exact name of registrant as specified in its charter) Delaware 26-3302902 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 1331 West Powell Way Lehi, Utah 84043 or ☐ TRANSITION REPORT PURSUANT ...

Exhibit 99.1 Five9 Reports Record Revenue of $286 Million for the Third Quarter Q3 Enterprise AI Revenue Growth of 41% Q3 Record Operating Cash Flow of $59 Million Announces $150 Million Share Repurchase Program SAN RAMON, Calif. - November 6, 2025 - Five9, Inc. (NASDAQ:FIVN), the Intelligent CX Platform provider, today reported results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results "We're pleased with our third quarter results with Enterprise AI revenue growing 41% YoY ...

Financial Performance - Net income before federal income tax for Q3 2025 increased to $4.5 million from $3.0 million in Q3 2024, driven by a $1.1 million increase in total revenues and a $0.4 million decrease in total benefits and expenses [157]. - Year-to-date net income before federal income tax for the nine months ended September 30, 2025 decreased to $9.6 million from $11.3 million in the same period in 2024 [157]. - Total revenues for the nine months ended September 30, 2025 were $183.546 million, up from $181.527 million in 2024, reflecting a growth of 1.1% [186]. - Total income before federal income tax for the three months ended September 30, 2025, was $4.479 million, an increase of 47.5% compared to $3.037 million in the same period of 2024 [208]. Premiums and Insurance - Direct premium revenue increased 4% in Q3 2025 to $46.6 million from $44.7 million in Q3 2024, and increased 6% year-to-date to $135.3 million from $127.7 million [164]. - Direct first year premiums increased 8% in Q3 2025 to $9.5 million from $8.8 million in Q3 2024, and increased 23% year-to-date to $27.8 million from $22.6 million [165]. - The company issued $777.6 million in new insurance in the first nine months of 2025, reflecting growth in its in-force business [180]. - Life Insurance segment revenues for the three months ended September 30, 2025, totaled $47.582 million, slightly up from $47.345 million in 2024, driven by a $0.607 million increase in premiums [209]. - The Life Insurance segment's total premiums for the nine months ended September 30, 2025, were $94.582 million, an increase of 3.2% from $91.667 million in 2024 [213]. Claims and Expenses - Claims and surrenders increased to $124.594 million for the nine months ended September 30, 2025, up from $104.121 million in 2024, representing a 19.7% rise [193]. - Total benefits and expenses for the nine months ended September 30, 2025 were $173.940 million, compared to $170.263 million in 2024 [192]. - Claims and surrenders in the Life Insurance segment rose to $38.603 million for the three months ended September 30, 2025, up from $30.083 million in 2024, primarily due to increased matured endowments [221]. - Death claim benefits for the three months ended September 30, 2025, were $4,273,000, down 17.0% from $5,154,000 in the same period of 2024 [228]. Investment Performance - The company experienced a $3.3 million decrease in investment-related gains and losses primarily due to the BlackRock write-down [157]. - Net investment income increased by $1.7 million in Q3 2025, aided by a one-time dividend of $1.7 million from a limited partnership investment [170]. - Net investment income for the nine months ended September 30, 2025 was $53.663 million, compared to $52.404 million in 2024, marking a 2.4% increase [188]. - Investment related losses for the Life Insurance segment were $2.063 million for the three months ended September 30, 2025, compared to gains of $0.936 million in the same period of 2024 [218]. Assets and Capital - Total assets as of September 30, 2025 were $1.7 billion, with total direct insurance in force of $5.4 billion and total investments of $1.4 billion [159]. - The company's cash and invested assets as of September 30, 2025, amounted to $1.4 billion, with 88% invested in fixed maturity securities [231]. - The carrying value of fixed maturity securities increased to $1.27 billion as of September 30, 2025, from $1.22 billion at December 31, 2024, reflecting interest rate sensitivity [233]. - The company had no debt as of September 30, 2025, and anticipates meeting short-term and long-term cash needs through cash generated from insurance operations and invested assets [247]. Regulatory and Strategic Considerations - The company is subject to regulatory capital requirements that could affect its ability to access capital from insurance operations [263]. - CICA Domestic's required commission payments may exceed current resources due to significant growth in first year sales, prompting the exploration of additional capital options [265]. - CICA International exceeded the required minimum capital of $750,000 and maintained a premium to surplus ratio of 7 to 1 as of September 30, 2025 [266]. - The company entered into a coinsurance reinsurance agreement with RGA in the second quarter of 2024, ceding 50% of its final expense business to alleviate expense strain [261].

Financial Performance - Cash, cash equivalents, and investments in marketable securities totaled $152.2 million as of September 30, 2025, down from $167.9 million as of June 30, 2025, representing a decrease of approximately 9.9%[7] - The net loss for Q1 fiscal 2026 was $18.2 million, compared to a net loss of $15.4 million for the same period last year, indicating an increase in net loss of about 18.2%[10] - Total operating expenses for Q1 fiscal 2026 were $19.8 million, compared to $16.9 million for the same period in the previous year, representing an increase of approximately 16.9%[15] - The company reported an accumulated deficit of $422.0 million as of September 30, 2025, compared to $403.9 million as of June 30, 2025[15] - Total stockholders' equity decreased to $147.2 million as of September 30, 2025, down from $162.1 million as of June 30, 2025[15] Expenses - Research and development (R&D) expenses increased to $13.1 million for Q1 fiscal 2026, compared to $12.8 million for the same period last year, reflecting an increase of about 2.4%[8] - General and administrative (G&A) expenses rose to $6.7 million for Q1 fiscal 2026, up from $4.2 million in the prior year, marking an increase of approximately 59.5%[9] Clinical Development - The company expects topline results from the Phase 3 sunRIZE trial in congenital hyperinsulinism in December 2025[2] - Enrollment for the streamlined Phase 3 trial for tumor hyperinsulinism is underway, with topline results anticipated in the second half of 2026[6] - The company achieved alignment with the FDA on a streamlined clinical development path for the tumor hyperinsulinism program, reducing the need for a double-blind randomized placebo-controlled trial[6]

Revenue Growth - Net revenue for the three months ended September 30, 2025, increased by 11.7% to $784.5 million compared to $702.5 million in the prior year period [162]. - The Affordable Medicines segment net revenue grew by 7.8% to $460.7 million, driven by new product launches contributing $24.3 million [171]. - Specialty segment net revenue increased by 8.3% to $125.2 million, primarily due to increases from CREXONT® and UNITHROID® [177]. - AvKARE net revenue for the three months ended September 30, 2025 increased by 24.5% to $198.5 million, driven by growth in the government label channel [183]. - Consolidated net revenue for the nine months ended September 30, 2025 increased by 6.8% to $2.2 billion, primarily due to increased sales volume across all segments [186]. - Affordable Medicines net revenue for the nine months ended September 30, 2025 increased by 5.0% to $1.3 billion, driven by new product launches [196]. - Specialty net revenue for the nine months ended September 30, 2025 increased by 11.3% to $361.6 million, primarily driven by increases in CREXONT® and UNITHROID® [204]. - AvKARE's net revenue for the nine months ended September 30, 2025, increased by 8.4% to $533.99 million compared to $492.56 million in the prior year [210]. Cost and Expenses - Cost of goods sold rose by 17.9% to $510.5 million, attributed to increased sales volume and higher input costs [164]. - Selling, general, and administrative expenses increased by 16.1% to $137.8 million, mainly due to higher employee compensation and launch costs [166]. - Research and development expenses rose by 3.7% to $63.4 million, including a $22.5 million in-licensing payment for Omalizumab [167]. - Specialty SG&A expense for the three months ended September 30, 2025 increased by 21.1% compared to the prior year period, primarily due to launch costs associated with CREXONT® and BREKIYA® [180]. - Specialty R&D expense for the three months ended September 30, 2025 increased by 105.8% compared to the prior year period, primarily due to higher project spending [181]. - Specialty R&D expenses for the nine months ended September 30, 2025 increased by 75.9% compared to the prior year period, primarily due to increased in-licensing and upfront milestone payments [208]. Profitability - Gross profit margin decreased to 34.9% from 38.4% year-over-year, reflecting increased costs and price erosion [165]. - Operating income decreased by 20.8% to $70.3 million, impacted by higher costs and lower gross profit margins [162]. - Specialty gross profit as a percentage of net revenue decreased to 41.1% for the three months ended September 30, 2025, compared to 54.7% in the prior year period due to impairment charges [179]. - Gross profit rose by 29.9% to $104.09 million, with gross profit as a percentage of net revenue increasing to 19.5% from 16.3% [212]. - Operating income surged by 63.9% to $58.09 million, up from $35.44 million in the previous year [210]. Tax and Legal Matters - The effective tax rate for the three months ended September 30, 2025, was 447.2%, compared to 23.8% in the prior year, influenced by jurisdictional income mix and tax reforms [169]. - The One Big Beautiful Bill Act resulted in a reduction of the company's current income tax liabilities by $23.5 million during the reporting period [161]. - The contingent tax receivable agreement liability was approximately $141.4 million as of September 30, 2025, with payments of $3 million made during the nine months ended September 30, 2025 [222]. - The company reached a settlement in principle for opioid litigation, depositing $24.2 million into dedicated accounts as part of the settlement process [221]. Cash Flow and Investments - Cash provided by operating activities was $209.68 million, an increase of 18.4% from $177.02 million in the prior year [226]. - Net cash used in investing activities increased to $66.81 million, up 42.3% from $46.94 million in the prior year, primarily due to higher capital expenditures [228]. - The company expects to invest approximately $120 million in capital expenditures during 2025, including $20 million expected to be reimbursed by Metsera, Inc. [219]. - As of September 30, 2025, the company had $595.2 million available under the Amended New Revolving Credit Facility and $83 million under the Amended Rondo Revolving Credit Facility [217]. - The company made cash tax and other distributions of $38.8 million to AvKARE Sellers during the nine months ended September 30, 2025, compared to $14.4 million in the prior year [224].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-07172 BRT APARTMENTS CORP. (Exact name of Registrant as specified in its charter) Maryland 13-2755856 (State or other jurisdiction of (I.R.S. Employer Id ...

Financial Performance - Revenues for Q3 2025 were $467.5 million, an increase of $15.6 million, or 3.5%, compared to Q3 2024[5] - Operating income for Q3 2025 was $89.9 million, up from $71.3 million in Q3 2024[2] - Net income attributable to OUTFRONT Media Inc. increased by $16.7 million, or 48.3%, to $51.3 million in Q3 2025 compared to Q3 2024[20] - Adjusted OIBDA for Q3 2025 was $137.2 million, an increase of $20.1 million, or 17.2%, from Q3 2024[8] - Revenues for Q3 2025 were $467.5 million, an increase from $451.9 million in Q3 2024, representing a growth of approximately 3.9%[36] - Operating income for Q3 2025 was $89.9 million, compared to $71.3 million in Q3 2024, reflecting a year-over-year increase of about 26.5%[36] - Net income attributable to OUTFRONT Media Inc. for Q3 2025 was $51.3 million, up from $34.6 million in Q3 2024, marking a growth of approximately 48.7%[36] - Basic net income per common share increased to $0.29 in Q3 2025 from $0.20 in Q3 2024, a rise of 45%[36] - Total revenues for the nine months ended September 30, 2025, were $1,318.4 million, a slight decrease from $1,337.7 million in the same period of 2024[41] - Adjusted OIBDA for the nine months ended September 30, 2025, was $325.5 million, compared to $309.6 million for the same period in 2024, reflecting an increase of 5.7%[43] Segment Performance - Transit segment revenues rose to $112.4 million, an increase of $21.5 million, or 23.7%, compared to the same prior-year period[12] Expenses and Costs - Total expenses for Q3 2025 were $377.6 million, slightly down from $380.6 million in Q3 2024, indicating cost management efforts[36] - Total operating expenses for the nine months ended September 30, 2025, decreased by 3.9% to $683.5 million from $711.6 million in 2024[45] - Billboard property lease expenses for the nine months ended September 30, 2025, were $331.5 million, down 8.7% from $363.2 million in 2024[44] - Restructuring charges amounted to $0.3 million in Q3 2025, compared to no charges in Q3 2024, reflecting ongoing strategic adjustments[36] - The company incurred restructuring charges of $17.9 million during the nine months ended September 30, 2025[41] Cash Flow and Capital Expenditures - Operating cash flow for the nine months ended September 30, 2025, was $189.5 million, compared to $174.7 million for the same period in 2024[38] - Total capital expenditures for the nine months ended September 30, 2025, increased by $4.1 million, or 6.8%, to $64.0 million compared to the same prior-year period[23] - Capital expenditures for the nine months ended September 30, 2025, were $64.0 million, compared to $59.9 million in 2024[39] - The company reported a net cash flow used for financing activities of $86.1 million for the nine months ended September 30, 2025, compared to $413.0 million in 2024[39] Debt and Indebtedness - As of September 30, 2025, total indebtedness was $2.6 billion, excluding deferred financing costs[26] - The weighted average cost of debt was 5.4% as of September 30, 2025, down from 5.6% in the same prior-year period[18] - Long-term debt increased to $2,582.3 million as of September 30, 2025, from $2,482.5 million as of December 31, 2024[37] - Interest expense for Q3 2025 was $37.0 million, consistent with $37.1 million in Q3 2024, showing stable financing costs[36] Assets and Liabilities - As of September 30, 2025, total assets amounted to $5,210.5 million, a slight decrease from $5,215.2 million as of December 31, 2024[37] - Total current liabilities decreased to $510.7 million as of September 30, 2025, from $520.8 million as of December 31, 2024[37] Dividends - The company announced a quarterly dividend of $0.30 per share, payable on December 31, 2025[1] Other Financial Metrics - Adjusted OIBDA margin is a key performance indicator, calculated as Adjusted OIBDA divided by total revenues, highlighting operational strength[32] - The adjusted OIBDA margin for the nine months ended September 30, 2025, was 24.7%, up from 23.1% in the prior year[41] - The company reported a net gain on dispositions of $1.4 million in Q3 2025, compared to a loss of $1.5 million in Q3 2024, indicating improved asset management[36] - The company reported a net loss on dispositions of $2.6 million for the nine months ended September 30, 2025[41] - The company’s cash paid for direct lease acquisition costs was $41.3 million for the nine months ended September 30, 2025, compared to $42.7 million in 2024[42]

"We are pleased with the significant progress we have made in the third quarter," said Globalstar CEO, Dr. Paul E. Jacobs. "Our strong financial results reflect the team's successful execution of our business plan and product roadmap, from expanding our global ground infrastructure and progressing our next-generation C-3 satellite system, to launching our two-way Commercial IoT device on a global basis and advancing XCOM RAN sales through completion of a new supply agreement and receipt of an initial order ...

Exhibit 99.1 Mr. Auerbach added, "We anticipate the following key milestones over the next 12 months: (i) presentation of interim data from ALISCA™-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (H1 2026) and (ii) presentation of additional interim data from the ALI-4201/ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with exten ...